Antibodies specific for sclerostin

Details Antibodies specific for sclerostin Antibodies specific for sclerostin

2006-04-05

2009-08-25

Kemmerer, Elizabeth C. (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S135100, C424S139100, C424S141100, C424S142100, C530S387100, C530S387300, C530S387900, C530S388100, C530S388150, C530S389200

Reexamination Certificate

active

07578999

ABSTRACT:
A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. In particular, compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.

REFERENCES:
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6495736 (2002-12-01), Brunkow et al.
patent: 6803453 (2004-10-01), Brunkow et al.
patent: 7381409 (2008-06-01), Winkler et al.
patent: 2004/0158045 (2004-08-01), Brunkow et al.
patent: 2005/0106683 (2005-05-01), Winkler et al.
patent: 2007/0110747 (2007-05-01), Paszty et al.
patent: WO 00/32773 (2000-06-01), None
patent: WO 01/92308 (2001-12-01), None
patent: WO 02/24888 (2002-04-01), None
patent: WO 03/106657 (2003-12-01), None
Balemans, W., et al., “Increased Bone Density in Sclerosteosis is Due to the Deficiency of a Novel Secreted Protein (SOST),” Human Molecular Genetics, 10(5):537-543, 2001.
Bradley et al., “Modifying The Mouse: Design and Desire,” Bio/Technology (1992) 10:534-539.
Brunkow, M.E. et al. “Bone Dysplasia Sclerosteosis Results from Loss of the Sost Gene Product, A Novel Cystine Knot-Containing Protein,” American Journal of Human Genetics, 68(3):577-589, 2001.
Campbell et al., “Totipotency of Multipotentiality of Cultured Cells: Applications and Progress,” Theriogenology (1997) 47:63-72.
Hoffman et al., “BMP Signaling Pathways in Cartilage and Bone Formation,” Critical Review in Eukaryotic Gene Expression (2001) 11(1-3)23-45.
Lian et al., “Bone Formation: Osteoblast Lineage Cells, Growth Factors, Matrix Proteins, and the Mineralization Process,” Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4thEdition (1999) 14-29.
Mullins et al., “Transgenesis in the Rat and Larger Mammals,” J. Clin. Invest. (1996) 97(7):1557-1560.
Oshima et al., “TGF-β Receptor Type II Deficiency Results in Defects of Yolk Sac Hematopoiesis and Vasculogenesis,” Developmental Biology (1996) 179:297-302.
Pittenger et al., “Multilineage Potential of Adult Human Mesenchymal Stem Cells,” Science (1999) 284:143-147.
Pockwinse et al., “Expression of Cell Growth and Bone Specific Genes at Single Cell Resolution During Development of Bone Tissue-Like Organization in Primary Osteoblast Cultures,” Journal of Cellular Biochemistry (1992) 49:310-323.
Reddi, A. Hari, “Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and Dan,” Arthritis Res. (2000) 3:1-5.
Schmitt et al., “Bone Morphogenetic Proteins: An Update on Basic Biology and Clinical Relevance,” Journal of Orthopaedic Research (1999) 17:269-278.
Smith, “TGF β inhibitors, new and unexpected requirements in vertebrate development,” TIG (1999) 15(1):3-5.
Cook et al., J. Biol. Chem., 280(48):40177-186 (2005).
Keller et al., Nat. Struct. Mol. Biol., 11(5):481-488 (2004).
Albertsen et al., “A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21,”Nature Genetics, 7:472-479 (1994).
Balemans et al., “Localization of the Gene for Sclerosteosis to the van Buchem Disease-Gene Region on Chromosome 17q12-q21,”Am. J. Hum. Genet., 64:1661-1669 (1999).
Chan et al., “Á new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists,”Current Opinion in Investigational Drugs, 8(4):293-298 (2007).
Expert Opinion from Dr. Catalina Lopez-Correa, dated Mar. 6, 2009.
Li et al., “Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signalling,”Jour. Bio. Chem., 280(20); 19883-19887 (2005).
van Bezooijen et al., “Wnt but Not BMP Signaling Is Involving in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone Formation,”J. Bone. Miner. Res.22:19-28 (2007).
Written Submission of Eli Lilly & Company, dated Mar. 9, 2009, Opposition to European Patent No. 1133558.

Affiliated with

Also associated with

Rating

Antibodies specific for sclerostin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies specific for sclerostin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies specific for sclerostin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4131076